Announced
Completed
Financials
Sources
Press Release
Celgene Corporation -
Agreement and plan of merger
Celgene Corporation -
Press release
Celgene Corporation -
Investor Presentation
Celgene Corporation -
Agreement and plan of merger
Celgene Corporation -
Press release
Celgene Corporation -
Schedule 14D-9
Juno -
Form 10-Q
Juno -
Form 10-K
Juno -
Tags
pharmaceuticals & biotechnology
biotechnology
Biotechnology
United States
Public
Acquisition
Completed
Friendly
Single Bidder
Majority
Synopsis
Celgene Corporation, an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders, acquired Juno Therapeutics, a pioneer in the development of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications, for $9bn. Under the terms of the merger agreement, Celgene paid $87 per share in cash. “The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers. Juno’s advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene’s global leadership in hematology and adds new drivers for growth beyond 2020,” Mark J. Alles, Celgene’s Chief Executive Officer.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.